DuPont and Lonza join to produce HMOs
DuPont Nutrition & Health and Lonza Specialty Ingredients have announced an agreement under which biotechnology and specialty ingredient company Lonza will manufacture and supply Care4U 2’-FL – a human milk oligosaccharide (HMOs).
DuPont Nutrition & Health is a specialist in microbial technology, health and nutrition, and the development of HMOs is part of a larger microbiome investment strategy for the company.
“By engaging strategically with Lonza, DuPont will be able to accelerate commercialisation and offer high-quality HMOs to customers and prospects. The collaboration with Lonza will play a key role in DuPont’s business growth strategy by focusing on providing high-quality consumer health and wellness products,” said John Rea, global business unit leader – cultures, probiotics, food protection, HMO & fibers, DuPont Nutrition & Health.
“Partnering with DuPont, Lonza will apply its leading science and biotechnology expertise in consumer health and nutrition applications to develop and manufacture superior quality human milk oligosaccharide Care4U 2’-FL,” said Erasmo Schutzer, president of Lonza’s consumer health division.
Naturally present in human milk, human milk oligosaccharides (HMOs) have been shown to support digestive, immune and cognitive development in infants by modifying the gut microbiota. Infant formula attempts to mimic the nutritional composition of breast milk as closely as possible, and clinical studies have shown that Care4U 2’-FL contains more than 98% 2’-fucosyllactose, the most abundant of the more than 130 oligosaccharides in human milk. This makes Care4U 2’-FL one of the purest human milk oligosaccharide products on the market.